A Salivary miRNA Diagnostic Test for Autism
- Conditions
- Autism Spectrum DisorderDevelopmental Delay
- Interventions
- Other: Salivary collectionOther: Vineland Adaptive Behavior Scale-III AssessmentOther: Medical history questionaireOther: Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)Other: Mullen Scales of Early Learning
- Registration Number
- NCT02832557
- Lead Sponsor
- State University of New York - Upstate Medical University
- Brief Summary
The goal of this study is to validate a panel of miRNAs that distinguish children with autism spectrum disorder (ASD) from their non-ASD peers with a positive MCHAT-R. These biomarkers may allow earlier diagnosis of autism, allowing earlier service, and also help us to understand some of the changes in the brains of autistic children.
- Detailed Description
The central aim of this project is to validate a panel of expressed microRNA (miRNA) in the saliva of children identified at risk for developing ASD by the MCHAT-R. Further, this study aims to assess the value of the current panel as an adjunctive test that may increase specificity of MCHAT-R positive results, or affirm clinical diagnoses alongside the ADOS or other objective assessments.
The primary endpoints of this study are as follows:
1. Evaluate the diagnostic ability (sensitivity and specificity) of the current a salivary microtranscriptome panel for distinguishing children with ASD from their non-ASD peers.
2. Assess stability of the salivary microtranscriptome diagnosis over time, and interrogate longitudinal microtranscriptome levels relative to neuropsychological measures.
Secondary endpoints are the identification of microtranscriptome features whose concentrations correlate with ASD endophenotypes.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 998
- Age at enrollment: 24 months to 48 months (inclusive)
- MCHAT-R score of 3 or greater
- Parent/guardian must be fluent in spoken English (required to complete study specific questionnaires etc)
- confounding neurological (i.e. cerebral palsy, epilepsy), sensory (i.e. auditory or visual) impairments, and feeding tube dependence.
- history of extreme pre-term birth (< 32 weeks gestation)
- wards of the state
- Autistic subjects with known syndromic autism (attributed to a known genetic mutation)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description MCHAT-R Positive Vineland Adaptive Behavior Scale-III Assessment Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy. MCHAT-R Positive Salivary collection Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy. MCHAT-R Positive Medical history questionaire Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy. MCHAT-R Positive Autism Diagnostic Observation Schedule -2nd edition (ADOS-2) Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy. MCHAT-R Positive Mullen Scales of Early Learning Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
- Primary Outcome Measures
Name Time Method Salivary miRNA profile at the time of collect (from 18m to 6 years of age) Measures of miRNA abundance in saliva
- Secondary Outcome Measures
Name Time Method Measure of autistic behavior At time of enrollment (from 18m to 6 years of age) Autism Diagnostic Observation Schedule (ADOS) Composite Score (Autism Group Only)
Measures of early intellectual development At time of enrollment (from 18m to 6 years of age) Mullen Scales of Early Learning
Measures of adaptive function At time of enrollment (from 18m to 6 years of age) Vineland Adaptive Behavior Composite Score
Trial Locations
- Locations (1)
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States